Table 2.
Characteristics of Sorafenib Treatment of the Included Studies
| Author | Median Onset of Sorafenib (months) | Initial Dose (b.i.d.) | Median Duration (month) | Reduction (%) | Discontinuation (%) | Hand–Foot Skin Reaction (%) | Grade 3-4 (%) | Diarrhea (%) | Grade 3-4 (%) | Nausea and Vomiting (%) | Grade 3-4 (%) | Fatigue (%) | Grade 3-4 (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| de’Angelis et al. | 15.9 | 400 | - | 53.3 | 13.3 | 40 | 3.2 | 46.7 | - | 20 | - | 66.7 | - |
| Desimone et al. | 11 | 400 | - | 42.9 | 28.6 | 71.4 | - | 28.6 | - | - | - | - | - |
| Gomez-martin et al. | 1.3 | 400 | - | 19.4 | 3.2 | 54.8 | 3.2 | 77.4 | 12.9 | 6.5 | - | 16.1 | 16.1 |
| Invernizzi et al. | 2.7 | 400 | 7.3 | 62 | 84 | 62 | 2 | 48 | 24 | 30 | - | 42 | 30 |
| Jung et al. | - | - | 7 | - | 77.8 | - | - | - | - | - | - | - | - |
| Kang et al. | - | 400 | - | - | 86.7 | 8.9 | - | 13.3 | - | 2.2 | - | - | - |
| Kim et al. | 4.3 | 200 | - | 66.7 | 55.6 | 55.6 | 22.2 | 33.3 | 11.1 | - | - | - | - |
| López Ortega et al. | 12.3 | 400 | 13 | 33.3 | - | 16.7 | - | 75 | - | - | - | - | - |
| Martin et al. | 26 | 400 | 5.5 | 100 | 28.6 | 23.8 | - | 9.5 | - | - | - | 4.8 | - |
| Na et al. | 6 | 400 | - | 25 | - | 25 | - | 66.7 | 25 | - | - | - | - |
| Nagai et al. | - | 400 | - | 13.3 | 6.7 | 13.3 | - | - | - | - | - | - | - |
| Pfeiffenberger et al. | 1.5 | 400 | 3.7 | 66.7 | - | 55.6 | 0 | - | - | - | - | - | 0 |
| Pfiffer et al. | - | - | - | - | - | 25 | 25 | - | - | - | - | - | - |
| Piñero et al. | 2.1 | 400 | 3 | - | 90 | 10 | - | 30 | - | - | - | 40 | - |
| Sotiropoulos et al. | - | 400 | 6.5 | 14.3 | 28.6 | - | - | - | - | - | - | - | - |
| Sposito et al. | 6.9 | 400 | - | 53.3 | 66.7 | 60 | - | 40 | - | - | - | 26.7 | - |
| Staufer et al. | 2.3 | 200 | 1.7 | - | 76.9 | 23.1 | 10 | 61.5 | 30.8 | 15.4 | 7.7 | 15.4 | 0 |
| Tan et al. | - | 400 | - | 10 | 10 | 50 | - | 30 | - | - | - | - | 0 |
| Vitale et al. | - | 200 | 10 | 40 | 30 | 30 | 30 | 50 | 50 | - | - | 20 | 20 |
| Waghray et al. | 1.9 | 200 | 10.4 | - | 5.9 | 5.9 | - | 17.6 | - | 5.9 | - | 11.8 | 11.8 |
| Weinmann et al. | 3.9 | 400 | 8.9 | 72.7 | 63.6 | 54.5 | 27.3 | 81.8 | 45.5 | 63.6 | 18.2 | 72.7 | 18.2 |
| Yoon et al. | - | 400 | 2.4 | - | 30.8 | 61.5 | 23.1 | 30.8 | - | - | - | - | - |
| Zavaglia et al. | - | 400 | 2.3 | 90.9 | 36.4 | 45.5 | - | 18.2 | - | 27.3 | - | 54.5 | 18.2 |